Tissue Regenix Key Appointment at USA Subsidiary

RNS Number : 3400K

Tissue Regenix Group PLC

29 July 2013

 



Tissue Regenix Appoints Patti Johnston as Senior Director of Clinical Affairs at its USA Subsidiary Tissue Regenix Wound Care Inc

YORK, 29 July, 2013 - Tissue Regenix ('TRX'), the regenerative medical devices company, has appointed Patti Johnston as Senior Director of Clinical Affairs to work with healthcare professionals and partners to lead the clinical development of its dCELL® decellularised medical devices for USA markets.

Tissue Regenix established its USA subsidiary Tissue Regenix Wound Care Inc in November 2012 and has made rapid progress.

Patti joins Tissue Regenix Wound Care Inc at an important point in the company's development, following the partnership agreement announced in June with Community Tissue Services (CTS), one of the largest tissue banks in the USA, to develop dCELL® dermis products to target the wound care market. Chronic wounds alone affect 6.5 million patients at a cost of care greater than $25bn and the partnership between CTS and Tissue Regenix will allow the company's dCELL® treatments to revolutionise treatment.

Patti joins Tissue Regenix from Polyremedy where she was Director of US Sales.

Patti is also Owner and President of Positive Outcomes® Inc., a clinical and financial outcomes provider that has developed numerous tools to drive positive outcomes for use across care settings.  She has formed key relationships with industry specialists and is widely regarded as a leading expert in quality improvement and wound management. She has previously held roles at Systagenix, KCI and Hill-rom.

Greg Bila, President Tissue Regenix USA Inc commented: "Patti has a national reputation as a healthcare industry leader with a background in sales, wound management and development. Her appointment is a logical next step in our strategy to commercialise dCELL®.  Patti joins us at what is an exciting time for the company, and her clinical expertise will help us continue with the strong progress we have already made in targeting USA markets."

"Patti's appointment underlines our commitment to pushing forward the commercialisation of dCELL® treatments in partnership with healthcare professionals and working with them to improve wound care and achieve positive outcomes in the clinic."

Antony Odell, Managing Director of Tissue Regenix Group plc said: "Tissue Regenix works in close partnership with researchers and clinicians around the world to develop treatments that improve healing and patient outcomes and Patti's appointment gives Tissue Regenix Wound Care Inc a highly experienced clinical specialist who will work at a senior level with our partners and customers to tailor treatments for specific clinical needs.

"Tissue Regenix has developed a wide range of research partnerships, with Yale University, Pontifical University of Panama, NHSBT and Leeds University to develop dCELL® treatments and Patti's clinical experience and skills will play a key role in the ongoing application of dCELL® to treating wounds and replacing failed soft tissue body parts (including heart valves, meniscus and vascular patches)."

-ENDS-

For Further Information

Tissue Regenix Wound Care Inc:                                              [phone]

Greg Bila

Tissue Regenix Group Plc:                                                           [phone]

Antony Odell

Jefferies International Ltd:                                                         [phone]

Simon Hardy

Harry Nicholas

Newgate Communications:                                                        [phone]

Alistair Kellie                                                                                   

Andrew Adie    

Andrew Jones                                                                  

About Tissue Regenix

Tissue Regenix is a leading medical devices company in the field of regenerative medicine. The company's patented decellularisation ('dCELL®) technology removes DNA and other cellular material from animal and human tissue leaving an acellular tissue scaffold which is not rejected by the patient's body which can then be used to repair diseased or worn out body parts. The potential applications of this process are diverse and address many critical clinical needs such as vascular disease, heart valve replacement and knee repair.

 

Tissue Regenix was formed in 2006 when it was spun-out from the University of Leeds. The company commercialises academic research conducted by our partners around the World.

In November 2012 Tissue Regenix Group plc set up a subsidiary company in the United States- 'Tissue Regenix Wound Care Inc.', as part of its commercialisation strategy for its dCELL® technology platform.

 

END

 

 

NRAPGURWMUPWUMB